
Ekskluderte studier

Eksklusjonsårsak: feil intervensjon

Gawronski K, Lehman K, Gardner D, Giannone P, Prasad M. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. *American Journal of Obstetrics and Gynecology* 2013;208 (1 SUPPL.1):S68.

Gawronski KM, Prasad MR, Backes CR, Lehman KJ, Gardner DK, Cordero L. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. *SAGE Open Med* 2014;2:2050312114530282.

Kreitinger C, Gutierrez H, Hamidovic A, Sarangarm P, Wohler E, Stephens E, et al. Effect of prenatal alcohol co-exposure and other factors on neonatal abstinence syndrome in infants born to opioid-dependent mothers. *Pharmacotherapy* 2013;33:e294.

McNicholas LF, Holbrook AM, O'Grady KE, Jones HE, Coyle MG, Martin PR, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. *Addiction* 2012;107:91-7.

Peles E, Sason A, Schreiber S, Adelson M. Newborn birth-weight of pregnant women on methadone or buprenorphine maintenance treatment: A national contingency management approach trial. *American Journal on Addictions* 2017;26(2):167-75.

Prasad M, Calaway B, Abdel-Rasoul M. Obstetric and neonatal sequelae of buprenorphine/naloxone (B/N) exposure versus methadone maintenance (MM). *American Journal of Obstetrics and Gynecology* 2013;208 (1 SUPPL.1):S201.

Siedentopf JP, Nagel M, Esser M, Casteleyn S, Dudenhausen JW. Experience with buprenorphine induction and subsequent dose reduction as compared to treatment with L-methadone in pregnant opiate addicts. [German]. *Geburtshilfe und Frauenheilkunde* 2004;64(7):711-8.

Wiegand S, Stringer E, Seashore C, Garcia K, Jones H, Stuebe A, et al. Buprenorphine/naloxone (B/N) and methadone (M) maintenance during pregnancy: A chart review and comparison of maternal and neonatal outcomes. *American Journal of Obstetrics and Gynecology* 2014;1):S368-S9.

Wiegand SL, Stringer EM, Stuebe AM, Jones H, Seashore C, Thorp J. Buprenorphine and naloxone compared with methadone treatment in pregnancy. *Obstet Gynecol* 2015;125(2):363-8.

Ekksklusjonsårsak: feil sammenlikning

Bauer RL, Kennedy MLH. Evaluation of neonatal and maternal outcomes after gestational exposure to buprenorphine vs. buprenorphine/naloxone combination products. *Journal of Pharmacy Practice* 2016;29 (3):280.

Jumah NA, Edwards C, Balfour-Boehm J, Loewen K, Dooley J, Gerber Finn L, et al. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. *BMJ Open* 2016;6(10):e011774.

Konijnenberg C, Jondalen NM, Husby MF, Melinder A. ERP correlates of cognitive control in children prenatally exposed to methadone or buprenorphine. *Developmental Neuropsychology* 2018:1-14.

Konijnenberg C, Melinder A. Executive function in preschool children prenatally exposed to methadone or buprenorphine. *Child Neuropsychology* 2015;21(5):570-85.

Miller C, Grynspan D, Gaudet L, Ferretti E, Lawrence S, Moretti F, et al. Maternal and neonatal characteristics of a Canadian urban cohort receiving treatment for opioid use disorder during pregnancy. *Journal of Developmental Origins of Health and Disease* 2018:1-6.

Rohrmeister K, Bernert G, Langer M, Fischer G, Weninger M, Pollak A. [Opiate addiction in gravidity - consequences for the newborn. Results of an interdisciplinary treatment concept]. *Z Geburtshilfe Neonatol* 2001;205(6):224-30.

Sarfi M, Smith L, Waal H, Sundet JM. Risks and realities: dyadic interaction between 6-month-old infants and their mothers in opioid maintenance treatment. *Infant Behavior & Development* 2011;34(4):578-89.

Ekksklusjonsårsak: feil studiedesign

Buprenorphine produces less withdrawal in babies than methadone. *Alcoholism & Drug Abuse Weekly* 2010;22(47):1-3.

Auriacombe M, Afflelou S, Lavignasse P, Lafitte C, Roux D, Daulouede JP, et al. [Pregnancy, abortion and delivery in a cohort of heroin dependent patients treated with drug substitution (methadone and buprenorphine) in Aquitaine]. *Presse Med* 1999;28(4):177.

Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. *American Journal on Addictions* 2004;13:S17-28.

Bandstra ES. Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses. *Addiction* 2012;107:1-4.

Blandthorn J, Forster DA, Love V. Neonatal and maternal outcomes following maternal use of buprenorphine or methadone during pregnancy: findings of a retrospective audit. *Women Birth* 2011;24(1):32-9.

Brar B, Jackson D, Nat M, Patil P, Iriye B, Planinic P. Antenatal interventions based upon fetal surveillance of the daily opioid exposed fetus: A descriptive analysis. *Journal of Maternal-Fetal & Neonatal Medicine* 2018:1-11.

Brogly SB, Saia K, Hernandez-Diaz S, Werler M, Sebastiani P. The comparative safety of buprenorphine versus methadone in pregnancy-What about confounding? *Addiction* 2016;111(12):2130-1.

Fischer G, Eder H, Jagsch R, Lennkh C, Habeler A, Aschauer H, et al. Maintenance therapy with synthetic opioids within a multidisciplinary program - A stabilizing necessity for pregnant opioid dependent women. *Archives of Women's Mental Health* 1998;1(3):109-16.

Fischer G, Eder H, Peternell A, Windhaber J. Quality of life in pregnant substance dependent women undergoing opioid maintenance therapy. [German]. *Nervenheilkunde* 2000;19(4):205-11.

Jimenez PW. Treatment impact and neurobehavioral effects of neonates with intrauterine exposure to buprenorphine versus methadone. *Dissertation Abstracts International: Section B: The Sciences and Engineering* 2018;79(9):No Pagination Specified.

John CS, Savitsky LM, Fowler J, Caughey AB. A cost effectiveness analysis of Buprenorphine vs. Methadone for maintenance of opioid addiction during pregnancy. *American Journal of Obstetrics and Gynecology* 2017;216:S449.

Lund IO, Fischer G, Welle-Strand GK, O'Grady KE, Debelak K, Morrone WR, et al. A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes. *Substance Abuse* 2013;7:61-74.

Pritham UA, Troese M, Stetson A. Methadone and buprenorphine treatment during pregnancy: what are the effects on infants? *Nursing for Women's Health* 2007;11(6):558-67.

Savage C. Buprenorphine and methadone treatment during the perinatal period. *Journal of Addictions Nursing (Taylor & Francis Ltd)* 2008;19(2):105-7.

Winhusen T, Wilder C, Wexelblatt SL, Theobald J, Hall ES, Lewis D, et al. Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome. *Contemporary Clinical Trials* 2014;39(1):158-65.

Ekksklusjonsårsak: utilstrekkelig informasjon

Christmas D, Rae C, Wright IM, Abdel-Latif ME, Clews S, Falconer, et al. Mr spectroscopic changes in infants exposed to prenatal opioids: A pilot study. *Journal of Paediatrics and Child Health* 2015;1:78.

Fowler J, Emerson J, Allen A, Dilley S, Gideonse N, Rieckmann T, et al. Buprenorphine vs methadone for maintenance of opioid addiction during pregnancy: A cost-effectiveness analysis. *American Journal of Obstetrics and Gynecology* 2013;208:S65-S6.

Krudy C, Alvarado F, Thomas M, Stark S, Ng M, O'Tierney-Ginn P, et al. Effect of opioid maintenance therapy on placental efficiency. *American Journal of Obstetrics and Gynecology* 2018;218 (1 Supplement 1):S370.

Ly V, Persad MD, Herrera K, Garry D, Garretto D. Does buprenorphine decrease the risk of neonatal abstinence syndrome in mothers with opioid use disorder? *Obstetrics and Gynecology* 2018;131 (Supplement 1):159S.

O'Brien SE, Geng D, Saia K, Shresthra H, Wachman EM. Maternal opioid agonist therapy and risk of congenital heart disease in the fetus. *Cardiology in the Young* 2017;27:S15.

Salari K, Romero V, Ehrenberg-Buchner S, Housey M, Vahratian A, Mozurkewich E. A comparison of neonatal outcomes in opioid dependent mothers with a history of substance abuse versus chronic pain. *American Journal of Obstetrics and Gynecology* 2012;1:S90.

Salari K, Romero V, Housey M, Ehrenberg-Buchner S, Vahratian A, Mozurkewich E. Correlation between maternal methadone or buprenorphine dose and neonatal abstinence syndrome. *American Journal of Obstetrics and Gynecology* 2012;1):S90.

Sarfi M, Heiervang E. Mental health and adaptation in 7/8 year-old children prenatally exposed to methadone and buprenorphine (OMT). *Alcohol and Alcoholism* 2014;1):i31-i2.

Seah J, Rae C, Wright I, Kaltenbach K, Oei JL. Do multiple maternal opioids reduce infant brain volume? *Journal of Paediatrics and Child Health* 2014;1:31.

Shah SS, Park L, Shaya FT. Comparison of buprenorphine and methadone based medication assisted treatments (MAT) for opioid use disorder (OUD) among pregnant women with commercial insurance. *Value in Health* 2018;21 (Supplement 1):S181.

Visconti K, Hennessy K, Towers C, Hennessy M, Howard B. Opiate abuse/usage in pregnancy and newborn head circumference. *American Journal of Obstetrics and Gynecology* 2013;208:S67-S8.